Pyxis Oncology, Inc.
PYXS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.02 | -0.01 | -0.01 |
| FCF Yield | -63.51% | -107.81% | -216.28% | -10.15% |
| EV / EBITDA | -1.40 | -1.06 | 0.95 | -1.14 |
| Quality | ||||
| ROIC | -61.11% | -55.09% | -67.12% | -28.60% |
| Gross Margin | 97.06% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.96 | 0.74 | 0.46 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 25.22% | 19.11% | -166.92% | -210.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.01 | -0.15 | 1.31 | 3.98 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.10 | 0.00 |
| Cash Conversion Cycle | -3,733.76 | -711.02 | -1,237.14 | -3,486.90 |